12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NewMet: Phase IIa data

A double-blind, crossover, U.S. Phase IIa trial in 24 Type II diabetics showed that twice-daily oral 500 and 1,000 mg doses of NewMet and 1,000 mg generic metformin led to similar significant reductions compared to baseline at day 5 in fasting plasma glucose (FPG) (16-22 mg/dL, p<0.01 for all) postprandial...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >